Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Dihydroartemisinin/piperaquine phosphate (Eurartesim®) is recommended as an option for use within NHS Wales for the treatment of uncomplicated Plasmodium falciparum malaria in adults, children and infants 6 months and over and weighing 5 kg or more. |
|||
|
|||
Medicine details |
|||
| Medicine name | dihydroartemisinin/piperaquine phosphate (Eurartesim®) | ||
| Formulation | 320 mg/40 mg film-coated tablet | ||
| Reference number | 1228 | ||
| Indication | Treatment of uncomplicated Plasmodium falciparum malaria in adults, children and infants 6 months and over and weighing 5 kg or more |
||
| Company | LogixX Pharma Solutions Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 1912 | ||
| NMG meeting date | 12/06/2012 | ||
| AWMSG meeting date | 18/07/2012 | ||
| Ratification by Welsh Government | 07/08/2012 | ||
| Date of issue | 13/08/2012 | ||
| Date of last review | August 2022 | ||
| Further information This appraisal recommendation was reviewed in August 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations |
|||